284 related articles for article (PubMed ID: 22307329)
1. DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Taira N; Mimoto R; Kurata M; Yamaguchi T; Kitagawa M; Miki Y; Yoshida K
J Clin Invest; 2012 Mar; 122(3):859-72. PubMed ID: 22307329
[TBL] [Abstract][Full Text] [Related]
2. Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Correa-Sáez A; Jiménez-Izquierdo R; Garrido-Rodríguez M; Morrugares R; Muñoz E; Calzado MA
Cell Mol Life Sci; 2020 Dec; 77(23):4747-4763. PubMed ID: 32462403
[TBL] [Abstract][Full Text] [Related]
3. Emerging roles of DYRK2 in cancer.
Tandon V; de la Vega L; Banerjee S
J Biol Chem; 2021; 296():100233. PubMed ID: 33376136
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Imawari Y; Mimoto R; Hirooka S; Morikawa T; Takeyama H; Yoshida K
Cancer Sci; 2018 Feb; 109(2):363-372. PubMed ID: 29193658
[TBL] [Abstract][Full Text] [Related]
5. Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Wang Y; Wu Y; Miao X; Zhu X; Miao X; He Y; Zhong F; Ding L; Liu J; Tang J; Huang Y; Xu X; He S
Int J Biol Macromol; 2015 Nov; 81():809-17. PubMed ID: 26341817
[TBL] [Abstract][Full Text] [Related]
6. ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.
Zhang Q; Yang Z; Jia Z; Liu C; Guo C; Lu H; Chen P; Ma K; Wang W; Zhou C
Mol Cancer; 2014 Jul; 13():181. PubMed ID: 25070240
[TBL] [Abstract][Full Text] [Related]
7. DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Mimoto R; Taira N; Takahashi H; Yamaguchi T; Okabe M; Uchida K; Miki Y; Yoshida K
Cancer Lett; 2013 Oct; 339(2):214-25. PubMed ID: 23791882
[TBL] [Abstract][Full Text] [Related]
8. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
9. Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Yan H; Hu K; Wu W; Li Y; Tian H; Chu Z; Koeffler HP; Yin D
PLoS One; 2016; 11(8):e0159954. PubMed ID: 27532268
[TBL] [Abstract][Full Text] [Related]
10. p38 Stabilizes Snail by Suppressing DYRK2-Mediated Phosphorylation That Is Required for GSK3β-βTrCP-Induced Snail Degradation.
Ryu KJ; Park SM; Park SH; Kim IK; Han H; Kim HJ; Kim SH; Hong KS; Kim H; Kim M; Yoon SJ; Asaithambi K; Lee KH; Park JY; Hah YS; Cho HJ; Yook JI; Yang JW; Ko GH; Lee G; Kang YJ; Hwangbo C; Kim KD; Park YJ; Yoo J
Cancer Res; 2019 Aug; 79(16):4135-4148. PubMed ID: 31209060
[TBL] [Abstract][Full Text] [Related]
11. Multiple functions of DYRK2 in cancer and tissue development.
Yoshida S; Yoshida K
FEBS Lett; 2019 Nov; 593(21):2953-2965. PubMed ID: 31505048
[TBL] [Abstract][Full Text] [Related]
12. The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling.
Chandrasekar B; Mummidi S; Valente AJ; Patel DN; Bailey SR; Freeman GL; Hatano M; Tokuhisa T; Jensen LE
J Biol Chem; 2005 Jul; 280(28):26263-77. PubMed ID: 15890643
[TBL] [Abstract][Full Text] [Related]
13. c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability.
Alarcon-Vargas D; Ronai Z
J Biol Chem; 2004 Feb; 279(6):5008-16. PubMed ID: 14625288
[TBL] [Abstract][Full Text] [Related]
14. Engagement of DYRK2 in proper control for cell division.
Nihira NT; Yoshida K
Cell Cycle; 2015; 14(6):802-7. PubMed ID: 25603354
[TBL] [Abstract][Full Text] [Related]
15. Dual-specificity tyrosine-regulated kinase 2 exerts anti-tumor effects by induction of G1 arrest in lung adenocarcinoma.
Harada E; Yoshida S; Imaizumi Y; Kawamura A; Ohtsuka T; Yoshida K
Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130600. PubMed ID: 38508285
[TBL] [Abstract][Full Text] [Related]
16. COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis.
Shao J; Teng Y; Padia R; Hong S; Noh H; Xie X; Mumm JS; Dong Z; Ding HF; Cowell J; Kim J; Han J; Huang S
Neoplasia; 2013 Sep; 15(9):1075-85. PubMed ID: 24027432
[TBL] [Abstract][Full Text] [Related]
17. Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer.
Kumamoto T; Yamada K; Yoshida S; Aoki K; Hirooka S; Eto K; Yanaga K; Yoshida K
Int J Oncol; 2020 Jun; 56(6):1529-1539. PubMed ID: 32236621
[TBL] [Abstract][Full Text] [Related]
18. Stability of the human pregnane X receptor is regulated by E3 ligase UBR5 and serine/threonine kinase DYRK2.
Ong SS; Goktug AN; Elias A; Wu J; Saunders D; Chen T
Biochem J; 2014 Apr; 459(1):193-203. PubMed ID: 24438055
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control.
Becker W
Cell Cycle; 2012 Sep; 11(18):3389-94. PubMed ID: 22918246
[TBL] [Abstract][Full Text] [Related]
20. c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis.
Lopez-Bergami P; Kim H; Dewing A; Goydos J; Aaronson S; Ronai Z
J Biol Chem; 2010 Jan; 285(2):903-13. PubMed ID: 19910471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
